Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a series of ...

Illumina has begun rolling out a series of updates to its top-of-the-line DNA sequencer models, with the goal of making the ...

Illumina (ILMN) announced a series of updates to its NovaSeq X Series, delivering the NovaSeq X single-flow-cell system alongside a software ...

New NovaSeq X 25B 100-cycle and 200-cycle kits enhance multiomic capabilities on NovaSeq X, and enable newly released Illumina Single-Cell Prep SAN DIEGO, Jan. 7, 2025 /PRNewswire/ -- Illumina ...

ClariMed, Inc., a global leader in human-centered medical device development and regulatory services, has announced the ...

MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into a clinical supply ...

Bernstein analyst Eve Burstein lowered the firm’s price target on Illumina (ILMN) to $140 from $145 and keeps a Market Perform rating on the ...

Rising Demand for Targeted Therapies and Advancements in Genomic Technologies Propel the Personalized Medicine Biomarkers market to a 14.54% CAGR ...

After hours: 7:08:30 p.m. EST ...